[1]黄伟炜 张和军 刘 健 吴 凡 陈木兰 王丽莉 李娜妮 李重颖.CDK4/6抑制剂联合曲妥珠单抗对乳腺癌裸鼠移植瘤抑制和转移的影响[J].福建医药杂志,2020,42(05):133-136.
点击复制

CDK4/6抑制剂联合曲妥珠单抗对乳腺癌裸鼠移植瘤抑制和转移的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年05期
页码:
133-136
栏目:
基础研究
出版日期:
2020-10-20

文章信息/Info

文章编号:
1002-2600(2020)05-0133-05
作者:
黄伟炜 张和军1 刘 健 吴 凡 陈木兰 王丽莉 李娜妮 李重颖
福建省肿瘤医院 福建医科大学附属肿瘤医院 福建中医药大学教学医院乳腺肿瘤内科(福州 350014)
关键词:
乳腺癌转移;  乳腺癌JIMT-1细胞;  裸鼠;  动物模型;  曲妥珠单抗;  哌柏西利
分类号:
R737.9
文献标志码:
A
摘要:
目的 观察曲妥珠单抗、哌柏西利、曲妥珠单抗+哌柏西利对HER-2阳性曲妥珠耐药细胞裸鼠移植瘤抑瘤效应及阻断肿瘤转移过程中黏附、突破基底膜、微血管生成作用的差异。方法 建立JIMT-1人乳腺癌细胞裸鼠移植瘤模型,分成曲妥珠单抗、哌柏西利、曲妥珠单抗+哌柏西利和对照组共4组,比较瘤重、抑瘤率。免疫组化法测移植瘤Ki67、血管内皮细胞生长因子(VEGF)、基质金属蛋白酶9(MMP9)、CD44v6表达。结果 与对照组相比,曲妥珠单抗、哌柏西利、曲妥珠单抗+哌柏西利组可明显抑制移植瘤生长(P<0.0001)。曲妥珠单抗、哌柏西利、曲妥珠单抗+哌柏西利组抑瘤率分别为29.4%、67.0%、76.5%。各组裸鼠肿瘤组织的MMP9、CD44v6低和中高表达的差异无统计学意义(P>0.05),VEGF、Ki67的差异有统计学意义(P<0.05)。用药后Ki67降低最多的为曲妥珠单抗+哌柏西利组,其后依次为哌柏西利、曲妥珠单抗组。用药后低表达VEGF比例最高的是曲妥珠单抗+哌柏西利组,其后依次为哌柏西利、曲妥珠单抗组。结论 曲妥珠单抗+哌柏西利联用较单药更能抑制肿瘤增殖。曲妥珠单抗、哌柏西利无论是单药还是联用,阻止肿瘤黏附、向基质侵袭的效果差,联用和单药均能抑制肿瘤血管生成,联用的效果更优。

参考文献/References:

[1] Slamon D J, Clark G M, Wong S G, et al.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science, 1987, 235(4785): 177-182.
[2] Puglisi F, Minisini A M, De Angelis C,et al.Overcoming treatment resistance in HER2-positive breast cancer: potential strategies[J].Drugs,2012,72(9):1175-1193.
[3] Scaltriti M, Chandarlapaty S, Prudkin L, et al.Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor[J].Clin Cancer Res, 2010, 16(9): 2688-2695.
[4] Roberts P J, Bisi J E, Strum J C, et al.Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy[J].Journal of the National Cancer Institute, 2012, 104(6):476-487.
[5] Finn R S,Martin M,Rugo H S,et al.Palbociclib and letrozole in advanced breast cancer[J].N Engl J Med,2016,375(20):1925-1936.
[6] Hortobagyi G N, Stemmer S M, Burris H A, et al.Ribociclib as first line therapy for HR-positive, advanced breast cancer[J].N Engl J Med, 2016, 375(18):1738-1748.
[7] Goetz M P, Toi M, Campone M, et al.MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol, 2017, 35(32):3638-3646.
[8] Diaz-Rodriguez E, Perez-Pena J, Rios-Luci C, et al.TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells[J].Cancer Lett, 2019, 453: 34-44.
[9] Yang L, Li Y, Bhattacharya A, et al.A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer[J].Sci Transl Med, 2019, 11(476):eaav1620.
[10] 谢韶,丁健,陈奕. CDK抑制剂在抗肿瘤领域的研发进展[J]. 药学进展, 2015, 39(10): 734-745.
[11] Herrera Gayol A, Jothy S.Adhesion proteins in the biology of breast cancer: contribution of CD44[J].EXP Mol Pathol,1999,66(2):149-156.
[12] Kleiner D E, Stetler Stevenson W G.Matrix metalloproteinases and metastasis[J].Cancer Chemother Pharmacol, 1999,43(suppl):S42-S51.
[13] Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[14] Muntasell A, Cabo M, Servitja S, et al.Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy[J].Front Immunol, 2017, 8:1544.
[15] Loi S, Giobbie-Hurder A, Gombos A, et al.Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer(PANACEA): a single-arm,multicentre, phase 1b-2 trial[J].Lancet Oncol, 2019, 20(3):371-382.
[16] Bang Y J,Giaccone G,Im S A,et al.First-in-human phase 1 study of margetuximab?(MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors[J].Ann Oncol,2017,28(4):855-861.
[17] Varella L, Abraham J, Kruse M.Revisiting the role of bevacizumab in the treatment of breast cancer[J].Semin Oncol,2017,44(4):273-285.

备注/Memo

备注/Memo:
基金项目: 福建省自然科学基金卫生联合资金面上项目(2018J01265) 1 病理科
更新日期/Last Update: 2020-10-20